Stifel Financial Corp Has $22.16 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Stifel Financial Corp cut its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 31.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 958,235 shares of the company's stock after selling 436,596 shares during the quarter. Stifel Financial Corp's holdings in Kenvue were worth $22,164,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the 3rd quarter valued at about $35,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after purchasing an additional 651 shares during the period. Studio Investment Management LLC raised its holdings in shares of Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock valued at $45,000 after purchasing an additional 845 shares during the period. Finally, Brooklyn Investment Group bought a new stake in shares of Kenvue in the 3rd quarter valued at about $71,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.03 on Monday, reaching $22.81. 15,266,374 shares of the company's stock were exchanged, compared to its average volume of 17,751,533. The company has a fifty day moving average of $22.97 and a 200-day moving average of $21.11. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a market capitalization of $43.73 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 2.07 and a beta of 1.37. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the business posted $0.31 EPS. The business's revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. Kenvue's dividend payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Royal Bank of Canada lowered shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price target on the stock. in a research note on Tuesday, September 24th. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. Finally, Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.